Outlook Therapeutics, Inc.

Name: Outlook Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

OTLKNasdaqCIK 1649989HealthcareFiscal year ends Sep 30

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue−$91.8k, Q4 FY2025

Operating income−$10.8m, Q3 FY2026

Net income−$20.3m, Q3 FY2026

Outlook Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q4 FY20232023-09-30	Q1 FY20242023-12-31	Q2 FY20242024-03-31	Q3 FY20242024-06-30	Q4 FY20242024-09-30	Q1 FY20252024-12-31	Q2 FY20252025-03-31	Q3 FY20252025-06-30	Q4 FY20252025-09-30	Q1 FY20262025-12-31	Q2 FY20262026-03-31	Q3 FY20262026-06-30
Revenue	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	1.5	(0.1)	not reported	not reported	not reported
Cost of revenue	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	0.4	0.9	0.0	0.1	0.0
Gross profit	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	1.1	(1.0)	(1.2)	(0.0)	(0.0)
Research and development	$m	4.9	4.5	13.5	11.2	12.5	9.7	4.4	7.1	6.0	3.6	4.5	3.3
Selling, general and administrative	$m	not reported	not reported	not reported	8.4	10.4	11.9	8.0	9.7	10.3	8.6	9.5	7.6
Operating income	$m	(12.5)	(10.3)	(18.9)	(19.6)	(22.9)	(21.6)	(12.4)	(15.7)	(17.3)	(13.5)	(14.0)	(10.8)
Interest expense	$m	0.0	not reported	not reported	not reported	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	0.0	not reported	0.0	0.0	0.0	not reported	0.0	0.0	(1.6)	not reported	not reported	not reported
Net income	$m	(13.0)	(11.2)	(114)	44.4	5.7	17.4	(46.4)	(20.2)	(13.3)	(23.1)	(4.5)	(20.3)
Diluted EPS	$ per share	not reported	(0.86)	(8.01)	(0.89)	not reported	0.72	(1.50)	(0.55)	not reported	(0.38)	(0.05)	(0.15)
Basic EPS	$ per share	not reported	(0.86)	(8.01)	1.91	not reported	0.72	(1.50)	(0.55)	not reported	(0.38)	(0.05)	(0.15)

Balance sheet

Cash and equivalents$11.2m, Q3 FY2026

Shareholders' equity−$10.4m, Q3 FY2026

Outlook Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	FY20232023-09-30	Q1 FY20242023-12-31	Q2 FY20242024-03-31	Q3 FY20242024-06-30	FY20242024-09-30	Q1 FY20252024-12-31	Q2 FY20252025-03-31	Q3 FY20252025-06-30	FY20252025-09-30	Q1 FY20262025-12-31	Q2 FY20262026-03-31	Q3 FY20262026-06-30
Cash and equivalents	$m	23.4	10.4	47.2	32.0	14.9	5.7	7.6	8.9	8.1	8.7	7.7	11.2
Current assets	$m	31.0	20.4	57.8	45.6	27.4	15.7	17.8	21.1	17.4	17.2	20.9	23.2
Total assets	$m	32.3	21.7	59.0	47.1	28.8	17.0	19.1	22.4	18.6	18.2	21.9	26.2
Current liabilities	$m	46.7	46.0	54.1	42.6	42.6	48.2	24.8	31.5	45.8	49.1	38.9	28.7
Total liabilities	$m	46.7	46.0	193	131	102	67.3	51.5	59.6	50.8	56.8	50.9	36.6
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	(14.4)	(24.3)	(134)	(83.7)	(73.1)	(50.3)	(32.5)	(37.2)	(32.2)	(38.5)	(29.0)	(10.4)

Cash flow

Operating cash flow−$21.0m, Q3 FY2026

Outlook Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q4 FY20232023-09-30	Q1 FY20242023-12-31	Q2 FY20242024-03-31	Q3 FY20242024-06-30	Q4 FY20242024-09-30	Q1 FY20252024-12-31	Q2 FY20252025-03-31	Q3 FY20252025-06-30	Q4 FY20252025-09-30	Q1 FY20262025-12-31	Q2 FY20262026-03-31	Q3 FY20262026-06-30
Operating cash flow	$m	(12.7)	(13.0)	(19.3)	(19.5)	(17.0)	(11.0)	(16.6)	(11.9)	(12.4)	(14.9)	(7.8)	(21.0)
Capital expenditure	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)136.74m, Q3 FY2026

Outlook Therapeutics, Inc., shares, quarterly
Line item	Unit	Q1 FY20232022-12-31	Q2 FY20232023-03-31	Q3 FY20232023-06-30	Q1 FY20242023-12-31	Q2 FY20242024-03-31	Q3 FY20242024-06-30	Q1 FY20252024-12-31	Q2 FY20252025-03-31	Q3 FY20252025-06-30	Q1 FY20262025-12-31	Q2 FY20262026-03-31	Q3 FY20262026-06-30
Diluted shares (weighted)	m shares	227	12.8	12.8	13.0	14.3	25.5	24.2	30.9	37.0	60.2	81.8	137

Shares outstanding: 243.45m at Aug 14, 2026, from the cover of the 10-Q filed Aug 18, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.